Explore

Rapid Read Rapid Read
Supreme Court Temporarily Restores Mail Access for Abortion Pill Amid Legal Dispute

Supreme Court Temporarily Restores Mail Access for Abortion Pill Amid Legal Dispute

The U.S. Supreme Court has issued a temporary stay on a lower court ruling that required patients to visit healthcare providers in person to obtain the abortion pill mifepristone. Justice Samuel Alito granted the administrative stay, which is effective until May 11, allowing the court more time to address the recent decision that disrupted abortion access by prohibiting the mailing of mifepristone. The manufacturers of the drug, Danco Laboratories LLC and GenBioPro Inc., requested the Supreme Court's intervention, arguing that the 5th U.S. Court of Appeals' decision created confusion by restricting access even in states where abortion remains legal. The 5th Circuit's ruling was a win for Louisiana, which challenged the FDA's rules permitting the pill's prescription by mail. The FDA had expanded access to mifepristone during President Joe Biden's administration, removing the requirement for in-person visits. Louisiana's lawsuit claimed the FDA relied on flawed data, while reproductive rights groups maintain...
Reuters Reuters
US Supreme Court lets abortion pill mail delivery restart for now

US Supreme Court lets abortion pill mail delivery restart for now

By Andrew Chung May 4 (Reuters) - The U.S.
Reuters Reuters
Abortion pill makers ask US Supreme Court to restore mail-order access

Abortion pill makers ask US Supreme Court to restore mail-order access

By Ismail Shakil May 2 (Reuters) - Two drugmakers have asked the U.S. Supreme Court to restore mail-order access to mifepristone, a move that would continue to allow women access to one of the most widely used abortion methods pending ongoing legal challenges.
Rapid Read Rapid Read
Justice Alito Temporarily Restores FDA Rule for Mailing Abortion Pill Mifepristone

Justice Alito Temporarily Restores FDA Rule for Mailing Abortion Pill Mifepristone

Justice Samuel Alito has temporarily halted an appellate court order that blocked the FDA's rule allowing the abortion pill mifepristone to be prescribed online and sent by mail. This decision grants temporary relief to Danco Laboratories and GenBioPro, the manufacturers of mifepristone and its generic version, respectively. The stay will remain in place until May 11, giving the Supreme Court time to consider the drug companies' requests to set aside the appellate court's order. The case has brought the issue of mifepristone's availability before the Supreme Court for the second time, following the overturning of Roe v. Wade in 2022.
Rapid Read Rapid Read
Supreme Court Asked to Maintain Mail Access for Abortion Drug Mifepristone

Supreme Court Asked to Maintain Mail Access for Abortion Drug Mifepristone

Danco Laboratories and GenBioPro have filed an emergency appeal to the Supreme Court, seeking to pause a lower court ruling that restricts mail-order access to the abortion drug mifepristone. The 5th U.S. Circuit Court of Appeals recently reinstated a requirement for in-person prescriptions, challenging the Biden administration's previous rule change that allowed mail distribution. Louisiana's lawsuit against the FDA argues that mail delivery of mifepristone facilitates illegal abortions and circumvents state bans. The appeals court's decision has prompted concerns about confusion and disruption in medical decision-making.
Rapid Read Rapid Read
Drugmakers Seek Supreme Court Intervention to Maintain Mail Access for Abortion Pill

Drugmakers Seek Supreme Court Intervention to Maintain Mail Access for Abortion Pill

Danco Laboratories and GenBioPro, manufacturers of mifepristone, have appealed to the U.S. Supreme Court to allow continued mail access to the abortion pill. This follows a ruling by the U.S. Court of Appeals for the Fifth Circuit that reinstated a requirement for in-person pickup of the drug, challenging the FDA's previous allowance for telehealth and mail distribution. The appeal highlights the unprecedented nature of the Fifth Circuit's order, which disrupts a long-standing distribution system. The legal battle comes in the wake of the Supreme Court's 2022 decision to overturn Roe v. Wade, prompting states to enact varying levels of abortion restrictions.
Rapid Read Rapid Read
Federal Court Blocks Mailing of Abortion Pill, Impacting Nationwide Access

Federal Court Blocks Mailing of Abortion Pill, Impacting Nationwide Access

A recent ruling by the 5th U.S. Circuit Court of Appeals has blocked the mailing of the abortion pill mifepristone, a decision that could significantly alter abortion access across the United States. The court's decision mandates that mifepristone, which was previously available via mail, must now be distributed in person at clinics. This ruling comes as a major victory for abortion opponents who argue that mail-order access undermines state bans on abortion. The decision has prompted Danco Laboratories, a manufacturer of mifepristone, to appeal to the Supreme Court to block the appellate court's ruling while further appeals are pending. The ruling affects all states, including those without abortion restrictions, and has sparked concerns about access for patients in remote areas.
Reuters Reuters
Danco seeks Supreme Court stay of ruling that pauses mail-order access to abortion drugs

Danco seeks Supreme Court stay of ruling that pauses mail-order access to abortion drugs

By Ismail Shakil May 2 (Reuters) - Pharmaceutical company Danco Laboratories filed an application with the U.S. Supreme Court on Saturday seeking a stay of an appeals court ruling that temporarily blocks the abortion drug mifepristone from being dispensed through the mail.
Rapid Read Rapid Read
Federal Appeals Court Restricts Mail-Order Access to Abortion Pill Mifepristone

Federal Appeals Court Restricts Mail-Order Access to Abortion Pill Mifepristone

A federal appeals court has issued a ruling that restricts the distribution of the abortion pill mifepristone by mail, mandating that it be dispensed only in person at clinics. This decision by the 5th U.S. Circuit Court of Appeals comes as a significant development in the ongoing legal battles over abortion access in the United States. The ruling challenges the FDA's regulations that previously allowed the pill to be prescribed via telehealth and mailed to patients, a practice that became more common during the COVID-19 pandemic. The court's decision is seen as a victory for abortion opponents who argue that mail-order access undermines state bans on abortion. The case is expected to be appealed to the Supreme Court, as Danco Laboratories, the manufacturer of mifepristone, has requested a stay on the ruling while appeals are pending.
Rapid Read Rapid Read
Federal Court Blocks Mailing of Abortion Pill, Impacting U.S. Access

Federal Court Blocks Mailing of Abortion Pill, Impacting U.S. Access

A federal appeals court has issued a ruling that blocks the mailing of mifepristone, a widely used abortion pill, marking a significant shift in U.S. abortion policy. The 5th U.S. Circuit Court of Appeals' decision requires that mifepristone be distributed only in person at clinics, overturning previous FDA regulations that allowed for its prescription via telehealth. This ruling is seen as a victory for abortion opponents who argue that the pill's distribution undermines state bans on abortion. The decision affects all states, including those without abortion restrictions, and is expected to be appealed to the U.S. Supreme Court.
Rapid Read Rapid Read
Federal Court Blocks Mail Distribution of Abortion Pill, Impacting Nationwide Access

Federal Court Blocks Mail Distribution of Abortion Pill, Impacting Nationwide Access

A federal court has blocked the distribution of the abortion pill mifepristone by mail, a decision that affects access to the drug across the United States. The ruling by the 5th U.S. Circuit Court of Appeals requires that mifepristone be distributed only in person and at clinics, overturning previous FDA regulations. This decision comes amid ongoing legal battles over abortion access following the overturning of Roe v. Wade. The ruling impacts patients in all states, including those without abortion restrictions, and has prompted manufacturers of the drug to seek emergency intervention from the Supreme Court.
Reuters Reuters
US court blocks mail-order access to abortion drugs, for now

US court blocks mail-order access to abortion drugs, for now

By Daniel Wiessner May 1 (Reuters) - A U.S. appeals court on Friday temporarily blocked a federal rule allowing the abortion drug mifepristone to be dispensed through the mail, significantly curtailing access to the drug nationwide and particularly in states that have banned abortion.